Cipla launches quality-assured Rectal Artesunate Suppositories for severe malaria in young children

Medicines for Malaria Venture (MMV), 25 July 2017

3 pp. 295 kB
https://www.mmv.org/sites/default/files/uploads/docs/press_releases/Press%20Releas
e%20-%20Cipla%20launches%20Rectal%20Artesunate%20Suppositories.pdf

Today, Cipla Ltd, a global pharmaceutical company, and MMV announce the launch of 100 mg Artesunate Rectocaps/Rectal Artesunate Suppositories (RAS), a life-saving, pre-referral intervention for the management of severe malaria in young children. Cipla’s RAS product is indicated in children from 6 months to 6 years. It was developed with the support of MMV (with UNITAID financing) and will now soon be available in four sub-Saharan countries.

(Visited 20 times, 1 visits today)
This entry was posted in Essential Medicines, General, Malaria. Bookmark the permalink.